Floatz logo

Avelumab

Stage IV Bladder Cancer AJCC v8

G1 Therapeutics, Inc.monoclonal_antibodyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

8 Active assets in the Stage IV Bladder Cancer AJCC v8 cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Fred Hutchinson Cancer Center
Phase 2BB
ENFORTUMAB VEDOTIN (fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting nectin-4)
Fred Hutchinson Cancer Center
Phase 2BB
Pembrolizumab
Fred Hutchinson Cancer Center
Phase 2BB
Epirubicin
Fred Hutchinson Cancer Center
Phase 2BB
Nivolumab
M.D. Anderson Cancer Center
Phase 2B
Bms-907351
National Cancer Institute (NCI)
Phase 2B
Ipilimumab
M.D. Anderson Cancer Center
Phase 2B
PROPRANOLOL
Emory University
Phase 2CCC

Same molecule, other indications

Avelumab is also rated in:

non-small cell lung carcinomaDormant
B
Indicative ·
58 / 100
View asset →
urothelial carcinomaDormant
B
Indicative ·
58 / 100
View asset →
bladder transitional cell carcinomaDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →